Revumenib has shown promising response rates in combination with oral decitabine-cedazuridine and venetoclax (SAVE regimen) in adults with R/R NPM1mut, NUP98-r, KMT2A-r AML [8]; ORR was 82% and CR/CRh rate 48%, 39% were consolidated with an HSCT and median duration of CR/CRh was not achieved with about 9 months median follow-up. The gene discussed is NUP98; the disease is acute myeloid leukemia.